Expedia Group EXPE

Reference table

1. What it is

Expedia Group (NASDAQ: EXPE) is one of the world's two dominant online travel agencies (OTAs), alongside Booking Holdings. It runs three segments:

• B2C (consumer): the household brands — Brand Expedia, Hotels.com, Vrbo (alternative accommodation), plus Orbitz, Travelocity, Hotwire, CheapTickets and others.
• B2B (Expedia Partner Solutions / Egencia): white-label travel technology and inventory sold to airlines, banks, corporate travel managers and other retailers. This is the fastest-growing, highest-quality part of the company (B2B revenue +25% YoY in Q1'26).
• trivago: a hotel metasearch site (majority-owned) that refers users onward to OTAs.

CEO Ariane Gorin (appointed 2024) leads a ~16,500-person company headquartered in Seattle. Fiscal year ends December 31.

Revenue mix (from filings & the Q1'26 release):

• By product (FY2025 FMP segmentation): Lodging $11.75B (~80% of the classified base) · Air $0.41B · plus advertising/media and other. Lodging is the engine; air is immaterial to profit.
• By segment (Q1'26): B2C $2.12B (+8%) · B2B $1.18B (+25%) · Other (trivago) $0.13B. B2B is now ~35% of revenue and the growth story.
• By geography (Q1'26 points of sale): U.S. $1.99B (58%) · Non-U.S. $1.44B (+24% YoY). International and B2B are where the growth is; the US base is mature.

The structural fact to hold onto: Expedia is a transaction-toll business — it inserts itself between the traveler and the hotel and takes a cut. That toll is lucrative (90% gross margin) but it depends on being the place travelers start their search. §2 and §11 are about whether that stays true.

2. The expert thesis — (traceable)

There is no net-bullish expert coverage of EXPE in the Synthos knowledge base. Breadth is 0 net-bullish voices; total_claims = 1, and that single claim is bearish. So this verdict is fundamentals- and quant-driven, not conviction-driven — and we say so plainly.

The one traceable voice is the cautionary one, and it goes to the heart of the bear case:

• Compound & Friends (compound_and_friends-LaCVAk3gSEc:4e86e1d7e6, bearish, conviction 72, skill 1.0, 2026-05-03): "Travel-booking middleman is disrupted — users just tell their LLM to book, meaning fewer visits, clicks and transactions." This is the AI-disintermediation thesis, and it is the single most important debate on the name.

We do not have a countervailing high-skill bull in the KB to weigh against it. That absence is itself information: the panel is not excited about this name, and our constructive-but-tactical call rests entirely on valuation and capital return doing the heavy lifting, despite the one expert voice leaning against. An honest note carries the founder's name — so we flag this as a low-conviction, quant/value call, not a high-conviction thesis.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them.

Synthos fair value = the base case, ~$300 (+12%), with the full $180–$385 span as the honest range. This anchor sits modestly above the Street's $270 consensus (we give credit to the buyback and B2B mix-shift) while our bear is below the Street's $240 low (we take the AI thesis seriously — the one expert on file is bearish). This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). EXPE is neither a fast compounder nor an exponential — it is a cheap, mature cash cow with a secular overhang:

• Forward growth: revenue CAGR FY25→FY30E only ~6.9% ($14.7B → $20.5B est). EPS CAGR is faster (~15%, FY26E $19.68 → FY30E $34.27) but that gap is buybacks and margin, not units.
• Acceleration (the 2nd derivative) is negative: revenue growth was +7.6% FY25 and consensus has it settling into a mid-single-digit-to-~7% band through 2030. There is no inflection here — if anything the AI question threatens the level, not just the slope.
• Room to run: the global travel TAM is enormous, and B2B/international are genuine growth legs. But TAM only matters if Expedia captures it — and the binding question is whether the OTA stays in the booking flow as AI agents mature. Nominal room to run does not rescue a disintermediation risk.
• Reinvestment runway: capex is light (~$0.77B, ~5% of revenue), so this is a return-capital story, not a reinvest-for-growth story — the opposite of an exponential. FCF goes to buybacks (new $5B authorization) and a dividend, not to a widening moat.

Exponential Potential: Low (3/10). Own EXPE for value and capital return, explicitly not for exponential growth. If AI agents commoditize search, even the cheap multiple is a value trap; if they don't, this is a 10–12% total-return cyclical. Neither is a multibagger.

5. Financials (real numbers — FMP annual/quarterly)

• Revenue: FY25 $14.73B, +7.6% (FY24 $13.69B, +6.6% on FY23 $12.84B). Steady, unspectacular — a post-COVID normalization now into a mature single-digit grind.
• Seasonality (why quarterly EPS swings wildly): travel books in spring, travels in summer, so Q3 is the cash cow (Q3'25 revenue $4.41B, EPS $7.33 diluted) while Q1 is a loss quarter (Q1'26 revenue $3.43B, diluted EPS −$0.05). Judge EXPE on the full year, not any single quarter.
• Margins: gross 90% TTM (a toll business), EBITDA margin ~20% TTM, net margin ~9.8% TTM. Adjusted EBITDA is the metric management steers by — Q1'26 Adj. EBITDA $542M (+83% YoY, +591bps margin), a genuine efficiency inflection.
• Earnings: net income $1.29B FY25 (+5%), diluted EPS $9.81 (vs $8.95 FY24). TTM EPS ~$12 reflecting the strong back half of 2025.
• Cash flow (the real story): operating CF $3.88B, capex −$0.77B, FCF $3.11B FY25 — a ~10% FCF yield on today's market cap. FCF comfortably exceeds GAAP net income (deferred-revenue float from prepaid bookings), which is a structural cash-generation advantage.
• Balance sheet: total debt $6.67B against $7.0B cash → net debt −$0.31B (net cash); ND/EBITDA −1.0×. Note the accounting quirk: book equity is tiny ($1.28B) after $16.8B of cumulative buybacks, so ROE (148%) and debt/equity (8×) are optically alarming but economically meaningless — the company has bought back most of its equity. Judge leverage on net cash and interest coverage (~7×), both healthy.

6. Valuation — priced in or room?

On the numbers, EXPE is genuinely cheap: 22× trailing EPS, 13.7× FY26E, 11.6× FY27E, ~8× FY30E, EV/EBITDA 9.0×, EV/sales 1.8×, and a ~10% free-cash-flow yield. That is roughly half the S&P's forward multiple. The PEG on trailing growth is 0.67 (cheap even after adjusting for growth).

The reason it's cheap is not a mystery — the market is applying a cyclicality discount plus a terminal-value discount (the AI-disintermediation question). The bull case is simply that ~10% FCF yield + a $5B buyback (~16% of the market cap) + steady B2B growth is too cheap for a business still growing. The bear case is that the cheap multiple is the market correctly pricing a business whose relevance is at risk — a value trap.

Street targets (context): consensus $270, high $330, low $240; the analyst tally is 34 Buy / 39 Hold / 2 Sell → a "Hold" consensus and a B+ quant letter rating. Our ~$300 base FV is modestly above consensus (crediting the buyback and B2B mix) but we anchor to the base case, not the Street. Not a growth-at-any-price name; a value-plus-capital-return name with a real overhang.

7. Technicals (from the tech block)

• Trend: up. $268.69 sits above the 50-DMA ($236.87) and 200-DMA ($242.42), with the 50 above the 200 (golden-cross posture). MACD +9.3 (positive).
• Location: −10.8% off the 52-week high ($301.31), +57% off the 52-week low ($171.01) — mid-to-upper range, max drawdown from peak −10.8% (a mild pullback).
• Momentum: RSI(14) 72 — overbought (>70). This is a stretched-entry warning: the stock has run hard and is short-term extended.
• Relative strength: EXPE +54.4% 12-mo vs SPY +20.6% and QQQ +30.3%; +18% 3-mo (vs SPY +14%, QQQ +22%) but −5.7% 6-mo (lagging both indices over that window). Strong 12-month leadership, choppier recently.
• Read: the trend is constructive but RSI 72 argues against chasing here. A better-risk entry is a pullback toward the rising 50-DMA (~$237) rather than at an overbought high. Technicals neither confirm nor deny the fundamental call; they just say don't lump in at the top tick.

8. Moat & competitive position

Expedia's moat is real but narrowing at the edges: (1) two-sided network + scale — millions of properties and travelers, and a data advantage from first-party booking history; (2) brand portfolio — Expedia, Hotels.com, Vrbo cover distinct traveler intents; (3) B2B technology — Expedia Partner Solutions is a genuinely sticky, high-growth platform embedding Expedia's inventory into third-party apps (banks, airlines). The 90% gross margin is the toll-booth signature.

The threats are structural: (a) the direct duopoly rival Booking Holdings is larger, more international and higher-margin; (b) Google has long squeezed OTA economics by inserting its own travel products above the fold; and (c) the new one — generative-AI booking agents that could let travelers bypass the OTA search box entirely (the compound_and_friends bear thesis). Expedia's defense is its own agentic tools, API access for AI partners, and first-party supply — but this is unproven.

Peer set (FMP, market cap — note: a generic consumer-cyclical basket, not travel-pure): the closest read-through is InterContinental Hotels $25B (a supplier, not a rival); the rest — Darden $23B, Restaurant Brands $26B, PulteGroup $25B, Rollins $21B, Ulta $20B, Viking $45B, Williams-Sonoma $27B, Tractor Supply $17B, Geely $24B — are same-size consumer cyclicals, not OTAs. The economically relevant comp (Booking Holdings) is absent from this list; BKNG is the higher-quality, higher-multiple benchmark the market judges EXPE against.

9. Management, capital allocation & guidance

• Capital allocation: shareholder-return-first, appropriately for a low-reinvestment cash cow. FY25 bought back $1.93B of stock and paid $0.20B in dividends; the board just authorized a new $5B buyback (~16% of the market cap) and pays a $0.48 quarterly dividend. Share count is falling fast (diluted shares ~132M FY25 vs ~150M FY23). This is the core of the bull case.
• Insider activity: the most recent transactions (2026-07-01) are routine director stock-unit awards (price $0). One notable open-market sale: the Chief Legal Officer sold 4,702 shares at $233 on 2026-06-05 — a single officer disposition, not a cluster; no alarming insider signal in the sampled window. (Board includes notable names — Barry Diller-era legacy, plus directors like Dara Khosrowshahi and Alexandr Wang.)
• Management's own guidance (half-weighted — they talk their book): the Q1'26 earnings release (SEC 8-K, filed 2026-05-07) is a real earnings release with explicit forward guidance. Management guided FY2026 gross bookings $127–129B (+6–8%), FY2026 revenue $15.6–16.0B (+6–9%), and Adjusted EBITDA margin expansion of +1 to +1.25 points; for Q2'26, gross bookings $32.5–33.1B (+7–9%), revenue $4.11–4.19B (+9–11%), and +0.5–1pt margin expansion. CEO Ariane Gorin framed Q1 as "the highest first-quarter profitability in our history" with double-digit bookings and revenue growth "despite a dynamic macroeconomic environment." This is management's own, self-interested framing — half-weighted by design — but it is consistent with the reported numbers (Q1'26 revenue +15%, Adj. EBITDA +83%) and corroborates the mid-single-digit-growth, margin-expansion, buyback base case.

10. Catalysts & what to watch

• Next earnings: 2026-08-06 (Q2'26; Street EPS $5.16, revenue ~$4.16B, in line with management's $4.11–4.19B guide). Q2 and Q3 are the seasonally strong prints that make the full-year number.
• B2B growth rate: B2B was +25% in Q1'26 — the single best thing in the business. Watch it stays >20%.
• AI / agentic-booking evidence: any data on traffic, conversion, and Expedia's own AI tools vs. disintermediation — the swing factor for the whole terminal value (compound_and_friends-LaCVAk3gSEc:4e86e1d7e6).
• Buyback pace: how fast the new $5B authorization retires shares directly drives EPS.
• Travel-demand macro: bookings and ADR trends as a recession tell — this is a cyclical.

Thesis tripwires (what would change the call): two consecutive quarters of gross-bookings deceleration below mid-single digits; hard evidence of AI-driven traffic/conversion erosion; B2B growth dropping below ~15%; or the buyback slowing materially.

11. Key risks

• AI disintermediation (structural — the bear thesis): users increasingly let an LLM book travel, bypassing Expedia's sites → "fewer visits, clicks and transactions" (compound_and_friends-LaCVAk3gSEc:4e86e1d7e6). This is the reason the multiple is cheap and the reason it could stay cheap.
• Cyclicality: travel is discretionary and recession-sensitive — revenue collapsed to $5.2B in 2020. Beta 1.26. A consumer slowdown hits bookings directly.
• Competition: Booking Holdings (larger, more international, higher-margin) and Google (squeezing OTA search economics) are persistent structural pressures.
• Growth-quality / value-trap risk: EPS growth leans on buybacks and margin, not organic demand; if the top line stalls, the "cheap" thesis unwinds.
• Optical balance-sheet flags: ROE 148%, debt/equity 8× and negative tangible book look scary but are artifacts of heavy buybacks against tiny book equity — real leverage is net cash. Don't be spooked by the ratios, but know they're there.

12. Verdict, position sizing & monitoring

Buy — Tactical. EXPE is a cheap (13.7× FY26E, ~10% FCF yield), net-cash, cash-generative travel platform aggressively retiring its own shares (new $5B buyback) with a genuinely good, fast-growing B2B franchise. That combination is attractive enough to own — tactically. But the honest weights pull the other way on conviction: zero net-bullish expert voices, the only KB claim is bearish (AI disintermediation), the Street rates it a Hold, growth is decelerating and single-digit, and it's a cyclical trading at an overbought RSI 72. This is a value-and-capital-return trade, not a durable compounder — hence Tactical, not Core.

• Sizing: tactical/satellite, ~1–3% of a portfolio. Given RSI 72, prefer scaling in on a pullback toward the ~$237 50-DMA rather than chasing the high.
• Monitoring: re-underwrite on the §10 tripwires — above all, any hard evidence on the AI-disintermediation question, which is the whole terminal-value debate. Formal re-score each earnings print.
• Single biggest risk: AI booking agents disintermediating the OTA middleman — the exact thesis of the one expert on file.

This verdict is logged as a tracked Synthos call as of 2026-07-03 at $268.69.

Provenance & disclosures

• Traceability: 1 KB claim, breadth 0 net-bullish, the single voice bearish (compound_and_friends-LaCVAk3gSEc:4e86e1d7e6, 2026-05-03) — reconciled to a real claim_id. There is no net-bullish expert coverage; this verdict is explicitly fundamentals/quant-driven. Fabricated conviction is structurally impossible (claim-ID reconciliation).
• Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · the one expert claim 2026-05-03. Forward figures are analyst consensus (FMP), labeled as estimates.
• Management caveat: the FY26/Q2'26 guidance in §9 is management's own earnings-release outlook (SEC 8-K, 2026-05-07), half-weighted by design.
• Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
• Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").